The study evaluated adjuvant treatment with the PD-L1 inhibitor durvalumab in patients with locally advanced esophageal or GEJ adenocarcinoma not achieving a pathological complete response after chemoradiation followed by radical resection. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.